Wang, Shaomeng

The PDBbind database: methodologies and updates

Wang, R., Fang, X., Lu, Y., Yang, C.-Y., & Wang, S. (2005) · Journal of Medicinal Chemistry

Computational Drug Discovery MethodsProtein Interaction Studies and Fluorescence Analysis

Cited by 933

Comparative evaluation of 11 scoring functions for molecular docking.

Wang, R., Lu, Y., & Wang, S. (2003) · Journal of Medicinal Chemistry

Computational Drug Discovery MethodsProtein Structure and Dynamics

Cited by 849

Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysComputational Drug Discovery Methods

Cited by 702

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 660

Structure-based design of potent non-peptide MDM2 inhibitors

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society

Cancer-related Molecular PathwaysComputational Drug Discovery Methods

Cited by 657

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell

Protein Degradation and InhibitorsCytokine Signaling Pathways and Interactions

Cited by 652

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 623

A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells

Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences

Cytokine Signaling Pathways and InteractionsComputational Drug Discovery Methods

Cited by 504

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 462

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 328

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Li, Y., Yang, J., Aguilar, A., McEachern, D., Przybranowski, S., Liu, L., Yang, C.-Y., Wang, M., Han, X., & Wang, S. (2019) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsCancer-related Molecular Pathways

Cited by 312

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 300

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression

Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 281

Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors

Zhao, Y., Liu, L., Sun, W., Lu, J., McEachern, D., Li, X., Yu, S., Bernard, D., Ochsenbein, P., Ferey, V., et al. (2013) · Journal of the American Chemical Society

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 234

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsCytokine Signaling Pathways and Interactions

Cited by 233

Discovery of 4-((3′ R ,4′ S ,5′ R )-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Aguilar, A., Lu, J., Liu, L., Du, D., Bernard, D., McEachern, D., Przybranowski, S., Li, X., Luo, R., Wen, B., et al. (2017) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 211

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research

Protein Degradation and InhibitorsHistone Deacetylase Inhibitors Research

Cited by 199

Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders

Yang, J., Li, Y., Aguilar, A., Liu, Z., Yang, C.-Y., & Wang, S. (2019) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 190

Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction

Yu, S., Qin, D., Shangary, S., Chen, J., Wang, G., Ding, K., McEachern, D., Qiu, S., Nikolovska-Coleska, Z., Miller, R., et al. (2009) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 180

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein

Wang, M., Lu, J., Wang, M., Yang, C.-Y., & Wang, S. (2020) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsProtein Tyrosine Phosphatases

Cited by 172

Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer

Han, X., Zhao, L., Xiang, W., Qin, C., Miao, B., McEachern, D., Wang, Y., Metwally, H., Wang, L., Matvekas, A., et al. (2021) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsProstate Cancer Treatment and Research

Cited by 170

cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation

McComb, S., Cheung, H. H., Korneluk, R. G., Wang, S., Krishnan, L., & Sad, S. (2012) · Cell Death & Differentiation

Cell death mechanisms and regulationNF-κB Signaling Pathways

Cited by 148

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species

Verhaegen, M., Bauer, J. A., Martín de la Vega, C., Wang, G., Wolter, K. G., Brenner, J. C., Nikolovska-Coleska, Z., Bengtson, A., Nair, R., Elder, J. T., et al. (2006) · Cancer Research

Cell death mechanisms and regulationMelanoma and MAPK Pathways

Cited by 140

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 91